Advertisement

Topics

Latest "Zenobia Therapeutics" News Stories - Page: 3

07:15 EST 19th February 2018 | BioPortfolio

Here are the most relevant search results for "Zenobia Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Zenobia Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Zenobia Therapeutics for you to read. Along with our medical data and news we also list Zenobia Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Zenobia Therapeutics Companies for you to search.

Showing "Zenobia Therapeutics" News Articles 51–75 of 6,400+

Probably Relevant

Mersana Therapeutics Announces Poster Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

CAMBRIDGE, Mass., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its proprietary Dolaflexin® platform, today announced that it will report preclinical data on  its second product candidate, XMT-1536, in a poster to be presente...


Waking Up the Immune System with Luc Dochez, CEO of Tusk Therapeutics

Tusk Therapeutics is developing antibodies to ignite the immune system response against cancer. We spoke with CEO Luc Dochez about Tusk and the oncology field. Tusk Therapeutics, based just north of London, focuses on therapeutic antibodies to boost the immune ... This awesome article Waking Up the Immune System with Luc Dochez, CEO of Tusk Therapeutics appeared first on Labiotech.eu. Be kind and ...

Transition Therapeutics licenses drug candidate from Eli Lilly

Transition Therapeutics announced its wholly-owned subsidiary, Transition Therapeutics Ireland Limited, has exclusively licensed worldwide rights to a novel small molecule drug candidate ("TT701") from Eli Lilly and Company. TT701 is a selective androgen receptor modulator that has been shown in a Phase 2 study to significantly increase lean body mass and a measurement of muscle more » The post T...


Spark Therapeutics, Inc.: Spark Therapeutics Enters into a Licensing and Supply Agreement for Investigational Voretigene Neparvovec Outside the U.S.

Novartis Pharmaceuticals will commercialize investigational voretigene neparvovec when and if approved in Europe and all other markets outside the U.S.; Spark Therapeutics retains U.S. commercial r...

Addex Therapeutics Ltd: Addex Therapeutics Equity Research Report Update Issued by valuationLAB

Report estimates a current value of ADXN of CHF 12.5 per share Geneva, Switzerland, 8 January 2018 - Addex Therapeutics (SIX: ADXN) announced today that the independent life science equity researc...

Adaptimmune Therapeutics (ADAP) & Celsion (CLSN) Critical Contrast

Adaptimmune Therapeutics and Celsion are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations. Adaptimmune Therapeutics currently has a consensus target price of $12.50, indicating a potential upside of 49.34%...

Arcturus Therapeutics Announces Expansion of Collaboration with Takeda Pharmaceuticals to Develop RNA-based Therapeutics for the Treatment of Nonalcoholic Steatohepatitis (NASH) and Other GI Disorders

SAN DIEGO, Jan. 17, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ:ARCT), a leading RNA medicines company, announced today that it is extending its partnership with Takeda Pharmaceutical Company Limited (TSE:4502) (Takeda). Under the collaboration, Takeda and Arcturus will advance their efforts to develop RNA-based therapeutics for the treatment of non-alcoholic steatohepatitis...

vTv Therapeutics out-licenses diabetes program in China, Pacific Rim

USA-based vTv Therapeutics has entered into a licensing agreement with Hangzhou Zhongmei Huadong Pharmaceutical…

Neon Therapeutics Enters License Agreement With The Netherlands Cancer Institute (NCI) For Neoantigen-Based T Cell Therapeutics

  Life Sciences Jobs   ...

ACORDA THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Acorda Therapeutics, Inc. To Contact The Firm

NEW YORK, NY / ACCESSWIRE / November 17, 2017 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Acorda Therapeutics, Inc. ("Acorda" or the "C...

Osiris Therapeutics (OSIR) and Jazz Pharmaceuticals (JAZZ) Critical Comparison

Osiris Therapeutics and Jazz Pharmaceuticals are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk and analyst recommendations. Osiris Therapeutics has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500.

Appointments: CRISPR, KSQ Therapeutics, Immunocore, Cellectis, Translate Bio and biOasis

This week's roundup includes CEO appointments by CRISPR Therapeutics and KSQ Therapeutics, in addition to various other board and high-level...    

#news #biotech Nektar Therapeutics reportedly considering a sale

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Nektar Therapeutics reportedly considering a sale .Nektar Therapeutics could join the growing list of biotechs opting for a takeover, according to a Bloomberg report that it is exploring … Continue reading → Cet article #news #biotech Nektar Therapeutics reportedly...

New British Spin-Out Wants to Replace Hormonal Menopause Treatment

KaNDy Therapeutics has been launched as a spin-out of NeRRe Therapeutics to develop a new treatment for menopause that can address multiple symptoms at once. NeRRe Therapeutics, a company built around targeting neurotransmitting peptides, has spun out a single-asset, virtual company named KaNDy Therapeutics that will ... This awesome article New British Spin-Out Wants to Replace Hormonal Men...

Soleno Therapeutics Receives Positive Opinion From European Orphan Committee For DCCR In Prader-Willi Syndrome

REDWOOD CITY, Calif., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the European Medicines Agencys (EMA) Committee for Orphan...

G1 Therapeutics to initiate Phase Ib/II trial for lung cancer

G1 Therapeutics has entered a clinical trial collaboration to assess its G1T38 in combination with AstraZeneca’s Tagrisso (osimertinib) in a...Read More... The post G1 Therapeutics to initiate Phase Ib/II trial for lung cancer appeared first on Drug Development Technology.

Spark Therapeutics, Inc.: Spark Therapeutics geht Lizenzierungs- und Liefervereinbarung für das Prüfpräparat Voretigene Neparvovec außerhalb der USA ein

Novartis Pharmaceuticals wird das Prüfpräparat Voretigene Neparvovec nach erfolgter Zulassung in Europa und allen anderen Märkten außerhalb der USA vermarkten; Spark Therapeutics behält die gewerb...

Contrasting Sarepta Therapeutics

Sarepta Therapeutics and Arrowhead Pharmaceuticals are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk and analyst recommendations. Arrowhead Pharmaceuticals has higher revenue, but lower earnings than Sarepta Therapeutics.

Bone Therapeutics et Transgene : 2 cotées qui montrent des signes positifs

La quotidienne de Biotech Finances avec Transgene et Bone Therapeutics Bone Therapeutics (BOTHE), thérapie cellulaire osseuse,  annonce l’obtention de résultats intermédiaires robustes, en termes de sécurité et d’efficacité, pour l’étude de phase IIA évaluant le produit allogénique ALLOB dans la fusion vertébrale lombaire. Les données, issues des 15 premiers patients de l’étud...

LifeArc and the Milner Therapeutics Institute Will Use AI to Find New Drug Targets

LifeArc and the Milner Therapeutics Institute have partnered up to use AI to find and test drug targets for cancer and respiratory diseases. LifeArc, a medical research charity in the UK, and the Milner Therapeutics Institute at Cambridge University have ... This awesome article LifeArc and the Milner Therapeutics Institute Will Use AI to Find New Drug Targets appeared first on Labiotech.eu. Be ki...

Spark Therapeutics, Inc.: Spark Therapeutics to Host Conference Call on Tuesday, Feb. 20 at 8:30 a.m. ET to Discuss 2017 Results and Recent Business Highlights

Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a conference call on Tuesday, Feb. 20, 2018, at 8...

Alnylam and Sanofi Enter Strategic Restructuring of RNAi Therapeutics Rare Disease Alliance

CAMBRIDGE, Mass. & PARIS–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Sanofi announced today a strategic restructuring of their RNAi therapeutics alliance to streamline and optimize development and commercialization of certain products for the treatment of rare genetic diseases. Specifically, Alnylam will obtain global d...

Carmot and Amgen to identify new therapeutics for Parkinson’s

US-based biotechnology firm Carmot Therapeutics and Amgen have signed a multi-year drug discovery collaboration and licensing agreement to identify new...Read More... The post Carmot and Amgen to identify new therapeutics for Parkinson’s appeared first on Pharmaceutical Technology.

Arcturus Therapeutics Announces Expansion of Collaboration with...

Arcturus Therapeutics Ltd. , a leading RNA medicines company, announced today that it is extending its partnership with Takeda Pharmaceutical Company Limited . Under the collaboration, Takeda and Arcturus will advance their efforts to develop RNA-based therapeutics for the treatment of non-alcoholic steatohepatitis and other gastrointestinal related disorders using Arcturus's wholly-owned LUNA...

Rapidly-growing Nektar Therapeutics reportedly considering sale of its business

After a slew of M&A deals throughout the first month of 2018, including Celgene’s buyout of Juno Therapeutics for $9 billion and Sanofi’s spending spree to acquire Bioverativ for $11.6 billion and Ablynx for $4.8 billion, many in the industry are asking who will be the next to make a deal. Whoever decides to splash the cash next, it could be to pick up Nektar Therapeutics, who is reported ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks